Powering Hearts
Beat to Beat

Expert Implanters on the AVEIR™ VR Ventricular Leadless Pacemaker (LP)

Abbott Cardiac Rhythm Management | February 10, 2024
 

Here at Abbott, there is so much happening in leadless pacemaker technology. Quickly adapting to changes in the world around us, AVEIR™ Leadless Pacemakers (LPs) are delivering the best possible solutions for some of the world’s most important health challenges. Let’s take a moment to sit down with Dr. Banker and Dr. Ip to get their thoughts on the benefits of this revolutionary technology specifically as it relates to single chamber ventricular pacing.

Designed for Long-Term Retrieval

Dr. Banker talks about the biggest advantage of AVEIR VR LP: it is the first leadless pacemaker on the market designed to be extracted after multiple years. This retrievability expands therapeutic options for patients, especially those who are younger where the risk of crowding the heart with devices over time is a real concern.

Long Lasting Battery

With an increased battery capacity, Dr. Ip mentions the AVEIR VR LP can last over 25 years, making this an ideal option for younger patients needing pacemakers implanted for intermittent pacing needs.

Among its Leadless II Phase 2 clinical trial patients at one-year follow-up, the AVEIR VR LP observed an impressive average battery life estimate of 17.6 years.⁴ Furthermore, 48% of the study’s patients had an estimated longevity of over 20 years.⁴

Mapping Prior to Fixation

Dr. Banker talks about how literature suggests that repositioning devices is associated with higher complication rates.⁵ The AVEIR VR LP mapping capability, with the ability to assess Current of Injury via Commanded EGM, initial pacing capture thresholds, sensing amplitudes, and impedance, is designed to help reduce the number of repositioning attempts.⁶

Upgradeability

Dr. Banker mentions that the AVEIR VR LP is designed for an upgradeable platform, the AVEIR™ DR Dual Chamber Leadless Pacemaker System,^7,8 to later support dual chamber pacing when patient therapy needs evolve. The option to upgrade over time allows you to meet your patient’s needs today and adapt to common disease progression later. Discover more about the AVEIR DR LP System.

Take a deeper dive into the AVEIR VR LP technology and all of its benefits here.

References

1. Reddy, VY, et al. Worldwide Experience with Leadless Pacemaker Retrievals: A Worldwide Nanostim Experience out of 9y. Presented at: APHRS 2022; Nov 18-20, 2022; Singapore.
2. AVEIR™ VR Leadless Pacemaker and Delivery Catheter IFU. ARTEN600175956
3. Micra^‡ VR IFU M991010A001 REV. B
4. Reddy VY, Exner D, et al. 1-Year Outcomes of a Leadless Ventricular Pacemaker: The LEADLESS II (Phase 2) Trial. JACC: Clinical Electrophysiology 2023, DOI: 10.1016/j.jacep.2023.01.031
5. Piccini J, Stromberg K, et al. Long-term outcomes in leadless Micra transcatheter pacemakers with elevated thresholds at implantation: Results from the Micra Transcatheter Pacing System Global Clinical Trial. Heart Rhythm Journal. May 2017; Vol 15: 5.
6. Reddy, VY et al. Primary Results on Safety and Efficacy from the LEADLESS II-Phase 2 Worldwide Clinical Trial, JACC: Clinical Electrophysiology, 2021, ISSN 2405-500X, https://doi.org/10.1016/j.jacep.2021.11.002.
7. AVEIR™ DR FDA approval.
8. AVEIR™ Leadless Pacemakers and Delivery Catheter IFU. ARTEN600284235.

™ Indicates a trademark of the Abbott group of companies.

^‡ Indicates a third-party trademark, which is property of its respective owner.